rmHypoxia study:2>0IIV0t 9Ve 7 Apr 2009 09:44stnumlnageiclnhgbiclntumsizeifpiclnhp5iclnpelviclnrespc3pelreceircledisreceentsurvtimeostatedftimedfcensfailtypepelnode%8.0g%8.0g%8.0g%8.0g%8.0g%8.0g%9.0g%9.0g%9.0g%9sg%9sg%9.0g%9.0g%9.0g%8.0g%9.0g%8.0g%8.0g%8.0gU ffurationivisionivisionyesnoonyesnoesnoriginesnoesnoesnoesnoPatient IDW5?@Age (years)5?@Hemoglobin (g/l)?@Tumor size (cm)?@Interstitial fluid pressure (marker, mmHg)?@Hypoxia marker (percentage of meas. < 5 mmHg)?@Pelvic node involvement: N=Negative, E=Equivocal, Y=Positive?@Response after treatment: CR=Complete response, NR=No response?@Pelvic disease observed: CR=Complete response, NR=No response?@Distant disease observed CR=Complete response, NR=No response?@Time from diagnosis to death or last follow-up time (yrs)onse?@Status at last follow-up: 0=Alive, 1=Deadw-up time (yrs)onse?@Time from diagnosis to first failure or last follow-up (yrs)e?@Censoring variable: 1=Failure, 0=Censoredst follow-up (yrs)e?@Failure type: 1 if pelrec, 2 if disrec & not pelrec, 0 otherwise@1 if pelvic nodes negative or equivocal not pelrec, 0 otherwise@_dtahgb tumsize ifp hp5 pelviclnnote1$W5R$Pintilie, M. 2006. Competing risks: A practical perspective. West Sussex, England: John Wiley & Sons.D_dtahgb tumsize ifp hp5 pelviclnnote0$W5R$1Nw@AIBNCR/@/@E@33Ad! @NCR A A7~ A AeMQBNNR?D;7A33S@P@NCR)\?X?2_AAfܪBYNRB`?D;9AA֚ANCR^@^@5@ffA1P2BECRCACA>@AnBNCRF@l@ @AUUANCRJ AJ A 9@@AmBNCRAA J|@ABANCRGY@GY@ C@LA^CBYNRJ ?D; H@33AUUBNCRjl@̬?BtAApBENRG!?D;/R AABYCRAo?=v@̼A\BNCRr@Zd?N_@A33BNNR%@D;4@1AcBNCR@@!w@iA)PBNCR/?Nbp?-}@33A;BNCR@@&A̜A/BECRy@y@7 AAjuBNCR%??i@|AKAYNRM?D;F}@pABNCRB`@B`@K@@33SABYCR@@G@ffArgBNCR@@/r@ffA=BBECRwG@w?C@33@}DANCR@@@B BNNR1?D; 7{@$AкBNCR@@!&d@33AnBECR@@"@33cA9kBYCR/@L7!@#+p@̄A&IANCRٶ@ٶ@$0|@ff^AGANCR#1@?%$sA?B[BNNRD?D;&#t@hA}BNCR@@'Bc@33AXƮBNCR'1?'1?(H|@AM!ANCR@@)?`@̼AffANCRx@x@*D@A|BNCR1<@|?+B@ffABECRt@t@,6Aff By AECR@?-;|@33@sO3BNCR@@.H{@@IAECR@ ?/ @@̜AOBYCRx?F?0+u@BBNCR-r@9?1J@ffNA4ANCR#1@#1@2#m@ffA>AECR$@$@3)m@\AHBECRff@ff@4.~AffABNNRj?D;5A@@AANCR@@6.@AXYANCRf?f?79@@33AفBNCR9@9@8|@AfAECRX9T@X9T@9-@@̸A$.BNCR-5@&@:!z@AAANCR@@;1@33AȡBNCR??<=@@HAIhBNCR5^@5^@=!@33;AkBNCRʩ@ʩ@>C{@ffNAANCR@t@?By@333AANCR H@ H@@7w@̼A7BNCRD @5?A+i@AnrBECR'1(@{?BM@A8BNCR`@`@C5@33ABECR1@J ?D,zĄA@BYNRH?D;ED@A֔BYCR^?^?F3rA.BTBYNRO@D;G1{@33BBECRl@z?H@ AzBECRE@E@I _@0A)BENRHz?D;J@@ff(BkBECRh?ף0?KG`@`A7%BNCREV@EV@L)AA_BYCR(@(@M6|@AIBNCR33@-}?N.@ABECR&@&@O>j AABYCR%@}??P*|A̤A$lBNCR@@Q1T AAAYNRffF?D;R={@Bl(ANCRԨ@@S0m@33A^BYNR@D;TD@333@d!@YCR@@UJk@ABYCR8@8@V(@AT)?NCR(@?WA|@BECR#ۍ@#ۍ@X3{@ABYCRy@?5^?Y:@̐A`ANCRԐ@Ԑ@Z+u@Aq8lBNCRҁ@ҁ@[5@@ffA@oAECR98@r?\/@ANCR:@:@]Jz@A[@NCRc@c@^1yA8B13BNNR^)?D;_.@B@NCR @V?`3@33ABEANCR3@w?a/@AAECR#ۅ@#ۅ@b*AffAjAYNRP?D;c,|@A